These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 11316511)
1. Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome. Balint GA Pharmacol Ther; 2001 Jan; 89(1):17-27. PubMed ID: 11316511 [TBL] [Abstract][Full Text] [Related]
2. [HIV protease inhibitors (new possibilities in the treatment of HIV infection and AIDS)]. Bálint GS Orv Hetil; 1998 Jun; 139(24):1471-4. PubMed ID: 9658865 [TBL] [Abstract][Full Text] [Related]
3. The development of anti-HIV-1 drugs. Lu XF; Chen ZW Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415 [TBL] [Abstract][Full Text] [Related]
4. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher? Garbelli A; Riva V; Crespan E; Maga G Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620 [TBL] [Abstract][Full Text] [Related]
5. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008]. Zheng PR; Xue H; Xiao ZY; Liu G Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426 [TBL] [Abstract][Full Text] [Related]
6. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206 [TBL] [Abstract][Full Text] [Related]
7. Drugs for AIDS. Ray S; Fatima Z; Saxena A Mini Rev Med Chem; 2010 Feb; 10(2):147-61. PubMed ID: 20408798 [TBL] [Abstract][Full Text] [Related]
8. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). De Clercq E Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005 [TBL] [Abstract][Full Text] [Related]
9. Structural mechanisms of HIV drug resistance. Erickson JW; Burt SK Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401 [TBL] [Abstract][Full Text] [Related]
10. [Drugs active against retroviruses]. Brun-Vézinet F; Descamps D Rev Prat; 1997 Mar; 47(6):631-8. PubMed ID: 9183937 [TBL] [Abstract][Full Text] [Related]
11. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. Cohen CJ; Hunt S; Sension M; Farthing C; Conant M; Jacobson S; Nadler J; Verbiest W; Hertogs K; Ames M; Rinehart AR; Graham NM; AIDS; 2002 Mar; 16(4):579-88. PubMed ID: 11873001 [TBL] [Abstract][Full Text] [Related]
12. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Imamichi T Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086 [TBL] [Abstract][Full Text] [Related]
13. Current clinical treatments of AIDS. Murphy EM; Jimenez HR; Smith SM Adv Pharmacol; 2008; 56():27-73. PubMed ID: 18086408 [No Abstract] [Full Text] [Related]
14. [New therapeutic strategies in HIV infection-immune reconstitution and virus suppression]. Herzmann C; Düesberg U; Arastéh K Med Klin (Munich); 2004 Jun; 99(6):323-5. PubMed ID: 15221057 [TBL] [Abstract][Full Text] [Related]
15. HIV and AIDS. Gap between biology and reality in AIDS. Carr A; Cooper DA Lancet; 1998 Dec 19-26; 352 Suppl 4():SIV16. PubMed ID: 9872163 [No Abstract] [Full Text] [Related]
16. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Patel N; Abdelsayed S; Veve M; Miller CD Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025 [TBL] [Abstract][Full Text] [Related]
17. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Barbaro G; Scozzafava A; Mastrolorenzo A; Supuran CT Curr Pharm Des; 2005; 11(14):1805-43. PubMed ID: 15892677 [TBL] [Abstract][Full Text] [Related]
18. Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics. Holec AD; Mandal S; Prathipati PK; Destache CJ Curr HIV Res; 2017; 15(6):411-421. PubMed ID: 29165087 [TBL] [Abstract][Full Text] [Related]
19. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903 [TBL] [Abstract][Full Text] [Related]